KRAS and familial pancreatic carcinoma: For instance, KRAS overactivation in pancreatic cancer increases interleukin-6 (IL-6) secretion, which facilitates tumour development via the JAK1/STAT3 pathway and triggers reactive oxygen species generation and oxidative stress responses [31].